ELOQUENT 2

Title: A phase 3 randomised trial of Lenalidomide and Dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma.

Population: Patients who have had 1-3 prior lines of treatment.
May have had bortezomib or thalidomide.
Can only have had Lenalidomide if:
– Achieved at least Partial response
– Had max 9 cycles
– Are not refractory (no Progessive Disease within 9 months).

Resource Links

http://clinicaltrials.gov/ct2/show/NCT01239797?term=ELOQUENT+2&rank=1

https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020347-12/IE

« Back